454 related articles for article (PubMed ID: 36515657)
1. Prion therapeutics: Lessons from the past.
Shim KH; Sharma N; An SSA
Prion; 2022 Dec; 16(1):265-294. PubMed ID: 36515657
[TBL] [Abstract][Full Text] [Related]
2. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme.
Mead S; Khalili-Shirazi A; Potter C; Mok T; Nihat A; Hyare H; Canning S; Schmidt C; Campbell T; Darwent L; Muirhead N; Ebsworth N; Hextall P; Wakeling M; Linehan J; Libri V; Williams B; Jaunmuktane Z; Brandner S; Rudge P; Collinge J
Lancet Neurol; 2022 Apr; 21(4):342-354. PubMed ID: 35305340
[TBL] [Abstract][Full Text] [Related]
3. New approaches for the selection and evaluation of anti-prion organic compounds.
Cordeiro Y; Ferreira NC
Mini Rev Med Chem; 2015; 15(2):84-92. PubMed ID: 25723455
[TBL] [Abstract][Full Text] [Related]
4. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
[TBL] [Abstract][Full Text] [Related]
5. Prion Protein Devoid of the Octapeptide Repeat Region Delays Bovine Spongiform Encephalopathy Pathogenesis in Mice.
Hara H; Miyata H; Das NR; Chida J; Yoshimochi T; Uchiyama K; Watanabe H; Kondoh G; Yokoyama T; Sakaguchi S
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046443
[TBL] [Abstract][Full Text] [Related]
6. Prion encephalopathies of animals and humans.
Prusiner SB
Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
[TBL] [Abstract][Full Text] [Related]
7. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions.
Petsch B; Müller-Schiffmann A; Lehle A; Zirdum E; Prikulis I; Kuhn F; Raeber AJ; Ironside JW; Korth C; Stitz L
J Virol; 2011 May; 85(9):4538-46. PubMed ID: 21345946
[TBL] [Abstract][Full Text] [Related]
8. Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep.
Lim K; Kim SY; Lee B; Segarra C; Kang S; Ju Y; Schmerr MJ; Coste J; Kim SY; Yokoyama T; An SS
Int J Nanomedicine; 2015; 10(Spec Iss):241-50. PubMed ID: 26425091
[TBL] [Abstract][Full Text] [Related]
9. Detection of Abnormal Prion Protein by Immunohistochemistry.
Orge L; Lurdes Pinto M; Cristovão P; Mendonça P; Carvalho P; Lima C; Santos H; Alves A; Seixas F; Pires I; Gama A; Dos Anjos Pires M
J Vis Exp; 2023 May; (195):. PubMed ID: 37212578
[TBL] [Abstract][Full Text] [Related]
10. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
11. Enhanced virulence of sheep-passaged bovine spongiform encephalopathy agent is revealed by decreased polymorphism barriers in prion protein conversion studies.
Priem J; Langeveld JP; van Keulen LJ; van Zijderveld FG; Andreoletti O; Bossers A
J Virol; 2014 Mar; 88(5):2903-12. PubMed ID: 24371051
[TBL] [Abstract][Full Text] [Related]
12. Genetic and infectious prion diseases.
Prusiner SB
Arch Neurol; 1993 Nov; 50(11):1129-53. PubMed ID: 8105771
[TBL] [Abstract][Full Text] [Related]
13. Small Molecules with Anti-Prion Activity.
Mustazza C; Sbriccoli M; Minosi P; Raggi C
Curr Med Chem; 2020; 27(33):5446-5479. PubMed ID: 31560283
[TBL] [Abstract][Full Text] [Related]
14. Cellular prion protein gene polymorphisms linked to differential scrapie susceptibility correlate with distinct residue connectivity between secondary structure elements.
Soto P; Claflin IA; Bursott AL; Schwab-McCoy AD; Bartz JC
J Biomol Struct Dyn; 2021 Jan; 39(1):129-139. PubMed ID: 31900058
[TBL] [Abstract][Full Text] [Related]
15. Prion protein self-interaction in prion disease therapy approaches.
Rigter A; Priem J; Langeveld JP; Bossers A
Vet Q; 2011 Sep; 31(3):115-28. PubMed ID: 22029882
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology of Animal Prion Diseases.
Orge L; Lima C; Machado C; Tavares P; Mendonça P; Carvalho P; Silva J; Pinto ML; Bastos E; Pereira JC; Gonçalves-Anjo N; Gama A; Esteves A; Alves A; Matos AC; Seixas F; Silva F; Pires I; Figueira L; Vieira-Pinto M; Sargo R; Pires MDA
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801117
[TBL] [Abstract][Full Text] [Related]
17. Prion Type-Dependent Deposition of PRNP Allelic Products in Heterozygous Sheep.
Langeveld JP; Jacobs JG; Hunter N; van Keulen LJ; Lantier F; van Zijderveld FG; Bossers A
J Virol; 2016 Jan; 90(2):805-12. PubMed ID: 26512080
[TBL] [Abstract][Full Text] [Related]
18. Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.
Caramelli M; Ru G; Acutis P; Forloni G
CNS Drugs; 2006; 20(1):15-28. PubMed ID: 16396521
[TBL] [Abstract][Full Text] [Related]
19. Bovine spongiform encephalopathy in Japan: history and recent studies on oxidative stress in prion diseases.
Onodera T; Sakudo A; Wu G; Saeki K
Microbiol Immunol; 2006; 50(8):565-78. PubMed ID: 16924141
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic development of polymers for prion disease.
Teruya K; Doh-Ura K
Cell Tissue Res; 2023 Apr; 392(1):349-365. PubMed ID: 35307792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
